benzathine penicillin
Clemizole is a drug in clinical development for the treatment of hepatitis C virus (HCV) infection. Clemizole is a novel inhibitor of TRPC5 channels. Clemizole is an H1 antagonist. Clemizole, an antihistamine drug that was once widely used for treatment of allergic disease, was recently discovered to be a potent inhibitor (IC50, 24 nM) of the interaction between an HCV protein (NS4B) and HCV RNA. Although clemizole was widely used during the 1950s and 1960s, this was before contemporary regulatory requirements were established for new drug development, and there is very minimal information about its pharmacokinetics and metabolism. — NCATS
Clinical trial activity
24 trials · 59 clinical orgs · 0 marketing orgs
Earliest trial started Aug 1, 2001 (NCT01156740)
Timeline
Indications
Approved for
Studied for
- Acute Kidney Injury · Phase 4
- Carcinoma, Hepatocellular · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Healthy Volunteers · Phase 1
- Heart Diseases · Phase 2
- Hepatitis C · Phase 1
- HIV · Phase 3
- Rheumatic Heart Disease · Phase 2
- Sepsis · Phase 4
- Spondylarthritis · Phase 4
- Spondylitis, Ankylosing · Phase 4
- Staphylococcal Infections · Phase 4
- Syphilis · Phase 4
- Syphilis, Congenital · Phase 2
Mechanism of action
- PeptidoglycanDISRUPTING AGENT
Peptidoglycan disrupting agent
Chemistry & pharmacology
SMILES
ClC1=CC=C(CN2C(CN3CCCC3)=NC4=C2C=CC=C4)C=C1- Mol. weight
- 325.835 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBenzathine penicillin ↗
- NCATST97CB3796L ↗
- ChEMBLCHEMBL1407943 ↗
Also known as
- al-20
- al-20
- benzatine
- clemizole
- clemizole
- clemizole
- clemizole
- clemizole
- clemizole hcl
- clemizole hcl
- clemizole hcl
- clemizole hydrochloride
- clemizole hydrochloride
- clemizole hydrochloride
- lergopenin
- penicillin g, benzathine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07189208 | Phase 2 | Nov 1, 2025 | National Institute of Allergy and Infectious Diseases (NIAID), University of California, Los Angeles |
| NCT06921213 | Phase 2 | Oct 1, 2025 | Chiangmai University, Medical Research Council, Murdoch University, National University of Ireland, Stellenbosch University, University of London, University of Sydney, Wellcome Trust |
| NCT06707194 | Phase 4 | Mar 1, 2025 | Southern Medical University |
| NCT06877351 | Phase 3 | Aug 14, 2024 | University of Buenos Aires |
| NCT06069141 | N/A | Oct 31, 2023 | Chiayi Christian Hospital, Chimei Medical Center, China Medical University, Far Eastern Memorial Hospital, Kaohsiung Medical University, National Cheng Kung University, National Taiwan University, Taipei Veteran General hospital, Taoyuan General Hospital |
| NCT06192277 | N/A | Oct 6, 2023 | Northern Ontario School of Medicine |
| NCT05693545 | Phase 2 | Sep 1, 2023 | Uganda Heart Institute, University of Cincinnati |
| NCT05548426 | Early Phase 1 (Phase 1) | Apr 30, 2023 | Cayetano Heredia University, University of Southern California, University of Texas at Houston |
| NCT05980871 | Phase 4 | Mar 10, 2023 | National Taiwan University |
| NCT05137119 | Phase 4 | Dec 1, 2021 | Berry Consultants, Menzies School of Health Research, Nanyang Technological University, Queensland University of Technology, Telethon Kids Institute, The Peter Doherty Institute, University of Melbourne, University of Queensland, University of Toronto |
| NCT04838717 | Phase 3 | Nov 30, 2021 | Assistance Publique - Hôpitaux de Paris |
| NCT05094154 | Phase 4 | Nov 10, 2021 | Vanderbilt University |
| NCT05069974 | Phase 3 | Oct 14, 2021 | FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA |
| NCT06907316 | Phase 4 | Jul 13, 2021 | Bulovka Hospital, Orebro University |
| NCT04958122 | Phase 3 | Jun 20, 2021 | AIDS Healthcare Foundation, Cayetano Heredia University, University of Southern California |
| NCT04454229 | N/A | Jun 1, 2021 | Austin Health, McGill University |
| NCT03752112 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2019 | World Health Organization |
| NCT03637660 | Phase 4 | Oct 18, 2018 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT03660488 | Phase 2 | Sep 30, 2018 | AIDS Healthcare Foundation, University of California, Los Angeles |
| NCT03612557 | Phase 1 | Aug 20, 2018 | Pfizer |